Completed PHASE3 INTERVENTIONAL 2-arm NCT04600895

The Prevent Severe COVID-19 (PRESECO) Study (PRESECO)

Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

Sponsor: Appili Therapeutics Inc.

Conditions Covid19

Updated 8 times since 2020 Last updated: Mar 27, 2024 Started: Nov 30, 2020 Primary completion: Oct 20, 2021 Completion: Oct 20, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04600895, this PHASE3 trial focuses on Covid19 and remains completed. Sponsored by Appili Therapeutics Inc., it has been updated 8 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2022 — Apr 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE3

▶ Show 3 earlier versions

Apr 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Appili Therapeutics Inc.

Data source: Appili Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boca Raton, United States , Bradenton, United States , Cuernavaca, Mexico , Hialeah, United States , Hollywood, United States , Houston, United States , Irapuato, Mexico , Juriquilla, Mexico , Kingwood, United States , Knoxville, United States and 17 more locations